Articles
Chicago, IL—Business intelligence is the process of collecting data from disparate systems internally and externally, and turning it into information that is meaningful and actionable toward achieving strategic goals.
In response to these gaps in the literature, Dr Palumbo and her colleagues sought to evaluate whether patient-centered therapy management software, in conjunction with use of electronic medical records (EMRs), would be valuable in completing pharmacist activities and capturing patient outcomes.
By Phoebe Starr
A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a preliminary phase 1b clinical trial.
By Wayne Kuznar
In a genomic study of more than 15,000 tumor samples, 16% of individuals with MSI-H tumors were later found to have Lynch syndrome. Zsofia Kinga Stadler, MD, Clinic Director, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York City, presented the results at a press briefing at ASCO 2018.
By Phoebe Starr
Chicago, IL—The current standard of care for women with early, HER2-positive breast cancer is 12 months of trastuzumab (Herceptin). Analysis of the phase 3 randomized clinical trial PERSEPHONE showed that 6 months of treatment with trastuzumab was noninferior to 12 months in terms of disease-free survival.
Ovarian cancer affects the glands found in women that produce eggs, known as ova, for reproduction. The American Cancer Society estimates that 22,240 women will be diagnosed with new cases of ovarian cancer in 2018, and 14,070 women will die from the disease during the same year.
In a recent survey, the average age of patients who used medical cannabis was 59.5 years, and approximately 27% were previous recreational cannabis users.
The November issue of The Oncology Pharmacist (TOP) features key presentations from the Hematology/Oncology Pharmacy Association 2018 Practice Management Conference.
Genotyping tumors for microsatellite instability (MSI) has taken on new importance in the world of oncology. MSI screening has long been recognized as important in the care of patients with colorectal cancer (CRC) or endometrial cancer, and high-level MSI (MSI-H) is now being recognized as a potential marker for germline mutations in certain DNA mismatch-repair (MMR) genes that lead to the development of Lynch syndrome.
Studies examining the landscape of MSI in various cancers have shown that different tumor types tend to exhibit instability at different microsatellite loci throughout the genome, and a PCR-based test that is limited to the evaluation of only 5 loci may not adequately capture this heterogeneity.